Briya launches first clinical-grade AI for medical and epidemiological research
Briya has announced the launch of Briya AIRE, the world’s first clinical-grade AI research assistant built to accelerate biomedical and clinical decision making.
Designed to “think” in the language of medicine, clinical research and epidemiology, AIRE turns months of manual data analysis into actionable insights in minutes – enabling faster, cost-effective discovery across biopharma and academic research sectors.
Robert Brown, MD, MPH is Vincent Astor Distinguished Professor of Medicine, Chief, Division of Gastroenterology and Hepatology at Weill Cornell Medicine.
He said: “Incorporating Briya AIRE into research and clinical practice has the potential to revolutionise medical care.
“Using AI to collate patient data and clinical evidence will allow physicians to make better decisions in a more efficient and timely manner while reducing administrative burden so they can spend more time interacting with and thinking about their patients.”
Unlike traditional AI tools that curate and synthesize data, Briya AIRE acts as a virtual epidemiologist and data analyst, helping researchers ask better questions and generate answers faster.
It is built to design patient cohorts, test hypotheses, refine study criteria, and identify data patterns otherwise missed.
By guiding researchers through these critical steps, Briya AIRE helps optimise study design and accelerate discoveries that can impact drug development and patient care.
Briya AIRE is being used by global academic medical centers, biopharma organisations and research institutions across a range of disciplines and therapeutic indications.
Its advanced natural language processing and analytical capabilities have already demonstrated potential to facilitate earlier diagnosis, enabling timely interventions for at-risk patients.
Gadi Lalazar, MD is Head of the Liver Unit, Shaare Zedek Medical Center, formerly affiliated with New York Presbyterian and Cornell.
Lalazar said: “Using the advanced NLP capabilities, we can now accurately identify patients with metabolic dysfunction-associated steatohepatitis (MASH) at significant risk of progressing to severe liver damage or cirrhosis, directly from unstructured clinical data across the healthcare ecosystem.
“This ability to automatically analyse imaging reports opens the door to earlier interventions for these high-risk patients, and spells promise for its use in a wide range of indications.”
David Lazerson, Co-founder and CEO of Briya, added: “Life-saving research should never be delayed because researchers and physicians are expected to become program coders.
“Unlike general-purpose AI tools, Briya AIRE has been built specifically for clinical and biomedical researchers to ask questions in plain language, instantly translated into epidemiologically valid and scientifically precise requests.
“The outcome is an accelerated research journey.”
